Cannistra SA - Search Results

1

Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA. Konstantinopoulos PA, et al. Among authors: cannistra sa. Cancer Res. 2011 Aug 1;71(15):5081-9. doi: 10.1158/0008-5472.CAN-10-4668. Epub 2011 Jun 15. Cancer Res. 2011. PMID: 21676886

2

Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.

Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Cannistra SA, et al. Cancer Res. 1993 Aug 15;53(16):3830-8. Cancer Res. 1993. PMID: 8339295

3

Absence of constitutive EGF receptor activation in ovarian cancer cell lines.

Ottensmeier C, Swanson L, Strobel T, Druker B, Niloff J, Cannistra SA. Ottensmeier C, et al. Among authors: cannistra sa. Br J Cancer. 1996 Aug;74(3):446-52. doi: 10.1038/bjc.1996.379. Br J Cancer. 1996. PMID: 8695362 Free PMC article.

4

BAX protein expression and clinical outcome in epithelial ovarian cancer.

Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. Tai YT, et al. Among authors: cannistra sa. J Clin Oncol. 1998 Aug;16(8):2583-90. doi: 10.1200/JCO.1998.16.8.2583. J Clin Oncol. 1998. PMID: 9704707

5

In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.

Tai YT, Strobel T, Kufe D, Cannistra SA. Tai YT, et al. Among authors: cannistra sa. Cancer Res. 1999 May 1;59(9):2121-6. Cancer Res. 1999. PMID: 10232598

6

Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. Spentzos D, et al. Among authors: cannistra sa. J Clin Oncol. 2004 Dec 1;22(23):4700-10. doi: 10.1200/JCO.2004.04.070. Epub 2004 Oct 25. J Clin Oncol. 2004. PMID: 15505275

7

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. Berkenblit A, et al. Among authors: cannistra sa. Gynecol Oncol. 2004 Dec;95(3):624-31. doi: 10.1016/j.ygyno.2004.08.028. Gynecol Oncol. 2004. PMID: 15581974 Clinical Trial.

8

Advances in the management of epithelial ovarian cancer.

Berkenblit A, Cannistra SA. Berkenblit A, et al. Among authors: cannistra sa. J Reprod Med. 2005 Jun;50(6):426-38. J Reprod Med. 2005. PMID: 16050567 Review.

9

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA. Spentzos D, et al. Among authors: cannistra sa. J Clin Oncol. 2005 Nov 1;23(31):7911-8. doi: 10.1200/JCO.2005.02.9363. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204010

10

A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy.

Comander AH, Cannistra SA. Comander AH, et al. Among authors: cannistra sa. Int J Gynecol Cancer. 2008 Jan-Feb;18(1):51-8. doi: 10.1111/j.1525-1438.2007.00978.x. Epub 2007 May 15. Int J Gynecol Cancer. 2008. PMID: 17506844

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters